CLINIXIR, A LEADING CONTRACT RESEARCH ORGANIZATION IN THAILAND, ANNOUNCES NEW CEO, DR. PUCHONG PADUNGSUTT

Dr. Puchong Padungsutt has assumed the role of CEO at Clinixir (www.clinixir.com), Thailand's leading contract research organization (CRO). Dr. Padungsutt brings to Clinixir more than two decades of leadership in the medical and pharmaceutical industries. His career has spanned high-level positions, including Vice President of Medical Affairs and Country Medical Director at Zuellig Pharma, where he led cross-functional teams and launched products in therapeutic areas such as Oncology, Women's Health, Immunology, Diabetes, Cardiovascular Health, and Vaccines. He assumes the role from Dr. Kanokwan Pornprasit, who takes the role of Advisor to the CEO of Clinixir after three years as CEO.

Dr. Padungsutt said, "It's a privilege to take the helm of one of Thailand's best-regarded contract research organizations. I look forward to continuing the excellent work overseen by Dr. Pornprasit for the past three years, and maintaining Clinixir's upward momentum as an organization trusted by companies around the world to conduct clinical research at the highest levels of safety, integrity, and innovation."

During his time at Zuellig Pharma, Dr. Padungsutt guided regulatory affairs, pharmacovigilance, and medical information services, while playing a pivotal role in developing Minimum Service Level frameworks and supporting medical launches across Southeast Asia. Before this, Dr. Padungsutt served as the Country Medical Director for Roche Thailand, where he led medical strategies, clinical trials, and initiatives like the MSL MOVE program. He also oversaw operations and medical activities in Thailand, Myanmar, Laos, and Cambodia.

Dr. Padungsutt began his career as a General Practitioner at the Air Force Hospital and Private Rangsit General Hospital, followed by academic roles at Siriraj Hospital's Gynecologic Oncology Unit, where he served as an instructor and assistant professor. His postdoctoral fellowship at Kitasato University in Japan, specializing in gynecologic oncology, further strengthened his academic and clinical expertise. His transition into the pharmaceutical sector began at Eli Lilly Thailand, where he worked as a Clinical Research Physician in Oncology, coordinating local studies and global clinical trials. At Novartis Oncology Thailand, Dr. Padungsutt served as Head of Medical Affairs, where he built and expanded medical teams, managed clinical trials in hematology and solid tumors, and executed local and global oncology studies.

Dr. Padungsutt is recognized for his expertise across multiple therapeutic areas, including oncology, women's health, immunology, infectious diseases, diabetes, cardiovascular health, bone health, and consumer health. His deep understanding of clinical operations, medical governance, regulatory compliance, and pharmacovigilance has made him a key figure in the medical industry. Additionally, his ability to develop medical strategies and support product pipelines from pre-launch to market access has been instrumental in driving patient access to innovative treatments across Southeast Asia.

Dr. Padungsutt is a sought-after speaker and thought leader who frequently shares his insights at industry events, focusing on medical strategy, clinical trials, and pharmaceutical advancements. Known for his ability to merge scientific excellence with practical healthcare solutions, he continues to make a significant impact on patient care and medical innovation.

Clinixir's Recent Accomplishments

• Clinixir just announced a strategic Memorandum of Understanding (MOU) with Burapha University. This partnership is poised to significantly enhance the capabilities of the BUU-CRC.
• Clinixir was invited to be part of the Good Clinical Practice (GCP) training regularly. Clinixir's Clinical Quality and Training Department led two insightful sessions, sharing our expertise and commitment to maintaining the highest standards in clinical research.
• Clinixir was appointed the local monitor for Tech Observer's phase III study, which is the second site initiated in Thailand. Thailand is the one of the five countries participating in the global phase III study.
• In late 2023, Clinixir was awarded a certificate by BSI for operating a Quality Management System which complies with the requirements of ISO 9001:2015 for the provision of Clinical Research Services.

About Clinixir

Clinixir is a leading clinical research organization based in Thailand, committed to advancing medical innovation through high-quality clinical trials. With a strong focus on safety, compliance, and scientific rigor, Clinixir partners with pharmaceutical, biotechnology, and medical device companies globally to facilitate the development of groundbreaking therapies. By leveraging state-of-the-art facilities and a highly experienced team of professionals, Clinixir ensures efficient trial execution and data integrity, playing a crucial role in bringing innovative treatments to market. For more information, visit www.clinixir.com.